PDCD1 and Lymphadenopathy: The earliest report was in 2009 by Eckert et al., who reported one case of developed cutaneous, pulmonary, mediastinal lymphadenopathy GSLs with anti-CTLA4, while the latest one was reported by Marcoval et al. in 2021 about a patient who developed cutaneous GSL upon using anti-PD1.